Early Switch to Oral Treatment in Patients with Moderate to Severe Community-acquired Pneumonia: a Meta-analysis

Overview

Journal Drugs

Specialty Pharmacology

Date 2008 Nov 20

PMID 19016574

Citations 23

Authors

Zoe Athanassa

Gregory Makris

George Dimopoulos

Matthew E Falagas

Affiliations

Soon will be listed here.

Abstract

Background: Early switch to oral antibacterials is recommended for the treatment of hospitalized patients with community-acquired pneumonia (CAP). However, its efficacy and safety in patients with more severe forms of CAP have not been well established.

Objective: To evaluate early switch to oral treatment in hospitalized patients with moderate to severe CAP.

Methods: Two reviewers independently extracted data from relevant randomized controlled trials (RCTs) with the same total duration of antibacterial treatment in the compared groups (early switch from intravenous to oral and conventional intravenous treatment for the whole duration of therapy).

Results: Six RCTs including 1219 patients fulfilled the criteria for inclusion in the meta-analysis. Treatment success was not different between early switch to oral treatment and intravenous only treatment groups in both intention to treat (odds ratio [OR] 0.76; 95% CI 0.36, 1.59) and clinically evaluable patients (OR 0.92; 95% CI 0.61, 1.39). Mortality and recurrence of CAP were not different (OR 0.81; 95% CI 0.49, 1.33 and OR 1.81; 95% CI 0.70, 4.72, respectively), while duration of hospitalization was shorter (weight mean difference -3.34; 95% CI -4.42, -2.25) and drug-related adverse events were fewer in the early switch group (OR 0.65; 95% CI 0.48, 0.89). Findings were similar in patients with severe CAP.

Conclusions: Early conversion to oral antibacterials seems to be as effective as continuous intravenous treatment in patients with moderate to severe CAP and results in substantial reduction in duration of hospitalization.

Citing Articles

Candent issues in pneumonia. Reflections from the Fifth Annual Meeting of Spanish Experts 2023.

Rodriguez-Leal C, Gonzalez-Corralejo C, Candel F, Salavert M Rev Esp Quimioter. 2024; 37(3):221-251.

PMID: 38436606 PMC: 11094633. DOI: 10.37201/req/018.2024.

Intravenous to Oral Antibiotic Switch Therapy Among Patients Hospitalized With Community-Acquired Pneumonia.

Deshpande A, Klompas M, Guo N, Imrey P, Pallotta A, Higgins T Clin Infect Dis. 2023; 77(2):174-185.

PMID: 37011018 PMC: 10527888. DOI: 10.1093/cid/ciad196.

Feasibility study of hospital antimicrobial stewardship analytics using electronic health records.

Dutey-Magni P, Gill M, McNulty D, Sohal G, Hayward A, Shallcross L JAC Antimicrob Resist. 2021; 3(1):dlab018.

PMID: 34223095 PMC: 8210026. DOI: 10.1093/jacamr/dlab018.

Empirical prescribing of penicillin G/V reduces risk of readmission of hospitalized patients with community-acquired pneumonia in Norway: a retrospective observational study.

Hogli J, Garcia B, Svendsen K, Skogen V, Smabrekke L BMC Pulm Med. 2020; 20(1):169.

PMID: 32539706 PMC: 7294665. DOI: 10.1186/s12890-020-01188-6.

Gaps between current clinical practice and evidence-based guidelines for treatment and care of older patients with Community Acquired Pneumonia: a descriptive cross-sectional study.

Eekholm S, Ahlstrom G, Kristensson J, Lindhardt T BMC Infect Dis. 2020; 20(1):73.

PMID: 31973742 PMC: 6979078. DOI: 10.1186/s12879-019-4742-4.

References

Oosterheert J, Bonten M, Schneider M, Buskens E, Lammers J, Hustinx W . Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. 2006; 333(7580):1193. PMC: 1693658. DOI: 10.1136/bmj.38993.560984.BE. View

Polic-Vizintin M, Leppee M, Stimac D, Vodopija I, Cindric J . Risk of pneumonia recurrence in patients previously hospitalized for pneumonia--a retrospective study (1998-2000). Coll Antropol. 2005; 29(1):213-9. View

Halm E, Fine M, Kapoor W, Singer D, Marrie T, Siu A . Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med. 2002; 162(11):1278-84. DOI: 10.1001/archinte.162.11.1278. View

Omidvari K, de Boisblanc B, Karam G, Nelson S, Haponik E, SUMMER W . Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med. 1999; 92(8):1032-9. DOI: 10.1016/s0954-6111(98)90351-1. View

Marrie T, Lau C, Wheeler S, Wong C, Vandervoort M, Feagan B . A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA. 2000; 283(6):749-55. DOI: 10.1001/jama.283.6.749. View

Mortensen E, Coley C, Singer D, Marrie T, Obrosky D, Kapoor W . Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 2002; 162(9):1059-64. DOI: 10.1001/archinte.162.9.1059. View

Rhew D, Tu G, Ofman J, Henning J, Richards M, Weingarten S . Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med. 2001; 161(5):722-7. DOI: 10.1001/archinte.161.5.722. View

Capelastegui A, Espana P, Quintana J, Gorordo I, Ortega M, Idoiaga I . Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis. 2004; 39(7):955-63. DOI: 10.1086/423960. View

Moher D, Pham B, Jones A, Cook D, Jadad A, Moher M . Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998; 352(9128):609-13. DOI: 10.1016/S0140-6736(98)01085-X. View

10.

Lee R, Lindstrom S . Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. Respirology. 2007; 12(1):111-6. DOI: 10.1111/j.1440-1843.2006.00931.x. View

11.

Lanbeck P, Odenholt I, Riesbeck K . Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. J Antimicrob Chemother. 2004; 53(2):174-9. DOI: 10.1093/jac/dkh056. View

12.

Siegel R, Halpern N, Almenoff P, Lee A, Cashin R, Greene J . A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest. 1996; 110(4):965-71. DOI: 10.1378/chest.110.4.965. View

13.

Halm E, Switzer G, Mittman B, Walsh M, Chang C, Fine M . What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia?. J Gen Intern Med. 2001; 16(9):599-605. PMC: 1495262. DOI: 10.1046/j.1525-1497.2001.016009599.x. View

14.

Guest J, Morris A . Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J. 1997; 10(7):1530-4. DOI: 10.1183/09031936.97.10071530. View

15.

Hedlund J, Ortqvist A, Kalin M, Giesecke J . Risk of pneumonia in patients previously treated in hospital for pneumonia. Lancet. 1992; 340(8816):396-7. DOI: 10.1016/0140-6736(92)91473-l. View

16.

Armengou-Arxe A, Garcia-Bragado F . Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med. 2001; 111(5):367-74. DOI: 10.1016/s0002-9343(01)00868-3. View

17.

Fine M, Auble T, Yealy D, Hanusa B, Weissfeld L, Singer D . A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243-50. DOI: 10.1056/NEJM199701233360402. View

18.

Mandell L, Wunderink R, Anzueto A, Bartlett J, Campbell G, Dean N . Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27-72. PMC: 7107997. DOI: 10.1086/511159. View

19.

Niederman M, McCombs J, Unger A, Kumar A, Popovian R . The cost of treating community-acquired pneumonia. Clin Ther. 1998; 20(4):820-37. DOI: 10.1016/s0149-2918(98)80144-6. View

20.

Lim W, van der Eerden M, Laing R, Boersma W, Karalus N, Town G . Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58(5):377-82. PMC: 1746657. DOI: 10.1136/thorax.58.5.377. View